2024 / 01

Next Paper
DOI: 10.47183/mes.2024.010

CLINICAL CASE

Intracoronary use of levocarnitine for coronary artery stent insertion in high-risk patients

Semigolovskii NYu1,2,3, Balluzek MF1,2, Guslev AB1,2, Mazurenko SO1, Kozaev AV2, Semenova IG2, Nikolskaya EM3, Scheglov AN4
About authors

1 Saint Petersburg State University, Saint Petersburg, Russia

2 Saint Petersburg Clinical Hospital of the Russian Academy of Sciences, Saint Petersburg, Russia

3 Clinical Hospital of the Sokolov North-Western District Scientific and Clinical Center of the Federal Medical Biological Agency, Saint Petersburg, Russia

4 Central Clinical Hospital with a Polyclinic of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia

Correspondence should be addressed: Nikita Yu. Semigolovskii
pr. Kultury, 4, Saint Petersburg, 194291, Russia; ur.xednay@iksvologimes

About paper

Funding: the study was performed as part of the State Assignment No. 075-01609-23-04 “Adjuvant Cytoprotection by Intracoronary Levocarnitine Administration during Revascularization in Patients with Acute and Chronic Coronary Syndrome” (FUEM-2023-0018). Research project No. 1022040701249-2-3.2.4. Agreement No. 075-03-2023-695/1 dated 21.04.2023.

Author contribution: Semigolovskii NYu — study concept and design, text development, literature review; Kozaev AN, Nikolskaya EM, Semenova IG — сollection and processing of material; Mazurenko SO — literature review, material analysis, editing; Guslev AB, Scheglov AN — material analysis; Balluzek MF — material analysis, editing.

Received: 2024-01-29 Accepted: 2024-03-17 Published online: 2024-03-25
|
  1. Serruys PW, Rutherford JD. The birth, and evolution, of percutaneous coronary interventions: a conversation with Patrick Serruys. Circulation. 2016; 134: 97–100. Available from: https://doi.org/10.1161/CIRCULATIONAHA.116.023681.
  2. Matskeplishvili S, Kontsevaya A. Cardiovascular Health, Disease, and Care in Russia. Circulation. 2021; 144 (8): 586–8. Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.055239.
  3. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023; 44 (38): 3720– 826. Available from: https://doi.org/10.1093/eurheartj/ehad191.
  4. Moghaddas A, Dashti-Khavidaki S. Potential protective effects of l-carnitine against neuromuscular ischemia-reperfusion injury: From experimental data to potential clinical applications. Clinical Nutrition. 2016; 35 (4): 783–90. Available from: https://doi.org/10.1016/j.clnu.2015.07.001.
  5. Vertkin AL. L-karnitin v medicinskoj praktike: dokazannye jeffekty. Nevrologija i revmatologija. 2012; 1: 83–86. Russian.
  6. Yoshihisa A, Watanabe S, Yokokawa T, Misaka T, Sato T, Suzuki S, et al. Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail. 2017; 4 (3): 360–4. Available from: https://doi.org/10.1002/ehf2.12176.
  7. Aronov DM. Realii i perspektivy primenenija L-karnitina v kardiologii. Rossijskij kardiologicheskij zhurnal. 2013; 5 (103): 73–80. Russian.
  8. Semigolovskii NYu, Vertinskiy EK, Azanov BA, Ivanova EV. Polozhitel'nye inotropnye svojstva levokarnitina pri sindrome malogo vybrosa u bol'nyh ostrym infarktom miokarda. Kardiologija i cerdechno-sosudistaja hirurgija. 2013; (3): 43–46. Russian.
  9. Glezer MG, Kiseleva AE, Astashkin EI. Vlijanie L-karnitina na dispersiju intervala QT u pacientov s ostrym koronarnym sindromom. Kardiologija. 2015; 55 (3): 4–9. Available from: https://doi.org/10.18565/cardio.2015.3.4-9. Russian.
  10. Zhao M, Jiang Q, Wang W, Geng M, Wang M, Han Y, et al. The roles of reactive oxygen species and nitric oxide in perfluorooctanoic acid-induced developmental cardiotoxicity and l-carnitine mediated protection. Int J Mol Sci. 2017; 18 (6). pii:E1229. Available from: https://doi.org/10.3390/ijms18061229.
  11. Pasechnik IN, Skobelev EI. Perspektivy metabolicheskoj terapii kriticheskih sostojanij. Doktor.Ru. 2015; 109 (8) — 110 (9): 22–27. Available from: https://www.elibrary.ru/item.asp?id=25137188. Russian.
  12. Xue YZ, Wang LX, Liu HZ, et al. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2007; 21: 445–8. Available from: https://doi.org/10.1007/s10557-007-6056-9.
  13. Semigolovskii NYu, Azanov BA, Ivanova EV, Bykov PV. Sluchaj uspeshnogo stentirovanija stvola levoj koronarnoj arterii u bol'noj s recidivirujushhim infarktom miokarda, oslozhnennym kardiogennym shokom i poliorgannoj nedostatochnost'ju. Klinicheskaja bol'nica. 2017; 21 (3): 36–41. Available from: https://pureportal.spbu.ru/files/96188822/Magazine_03_2017.pdf. Russian.
  14. Wang ZYu, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018; 194: 88–97. DOI: 10.1016/j.lfs.2017.12.015 PMID: 29241711.
  15. Semigolovskii NYu, Mazurenko SO, Semigolovskii SN, Shabalina MO. Sluchaj uspeshnogo lechenija polnoj atrioventrikuljarnoj blokady, oslozhnennoj vnezapnoj aritmicheskoj smert'ju, u bol'nogo starcheskogo vozrasta s trombocitopeniej v postkovidnom periode. Aterotromboz. 2021; 11 (2): 103–20. Russian.
  16. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992; 13 (8): 1109–15. Available from: https://doi.org/10.1093/oxfordjournals.eurheartj.a060322.
  17. Iosseliani DG, Koledinsky AG, Kuchkina NV. Does intracoronary injection of phosphocreatine prevent myocardial reperfusion injury following angioplasty of infarct-related artery in acute-stage of myocardial infarction? J Interv Cardiol. 2004; (6): 10–14. Available from: http://ijic.ru/en/pdf/06E.pdf.
  18. Voronin MS, Balluzek MF, Semigolovskii NYu. Citoprotektivnoe dejstvie levokarnitina pri intrakoronarnom vvedenii v hode chreskozhnyh koronarnyh vmeshatel'stv u ostryh koronarnyh bol'nyh. Sb. nauchn. trudov SPb bol'nicy RAN 2022. SPb.: POLITEH-PRESS, 2022; c. 113–20. Russian.
  19. Costell M, O'Connor JE, Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun. 1989; 161 (3): 1135–43. Available from: https://doi.org/10.1016/0006-291x(89)91360-0.
  20. Mahova AA, Shumjanceva VV, Shih EV, Bulko TV, Suprun EV, Kuzikov AV, et al. Reguljacija aktivnosti fermentov metabolizma lekarstvennyh preparatov — citohromov R450 3A4 i 2S9 — biologicheski aktivnymi soedinenijami. Molekuljarnaja medicina. 2013; 5: 49–53. Available from: https://molmedjournal.ru/archive/molecmed-2013-05-09.pdf. Russian.
  21. Makhova AA, Shich EV, Kukes VG, Sizova OS, Ramenskaya GV, Shumyantseva VV, et al. Electroanalysis of cytochrome P450 3A4 catalytik properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism. BioNanoScience. 2011; 1 (1–2): 46–52. Available from: https://link.springer.com/article/10.1007/s12668-011-0007-4.
  22. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-Carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013; 88 (6): 544–51. Available from: https://doi.org/10.1016/j.mayocp.2013.02.007. Epub 2013 Apr 15.
  23. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A MetaAnalysis of Randomized Controlled Trials. BioMed Research International. 2017; Article ID 6274854, 11 p. Available from: https://doi.org/:10.1155/2017/6274854.
  24. Efremova YuE. Jeffektivnost' i bezopasnost' primenenija L-karnitina pri hronicheskoj serdechnoj nedostatochnosti: metaanaliz randomizirovannyh kontroliruemyh issledovanij (referat). RMZh. 2017; 20: 1471–80. Russian.